Literature DB >> 17935823

Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer.

Maider Zabala1, Juan José Lasarte, Christine Perret, Josu Sola, Pedro Berraondo, Maite Alfaro, Esther Larrea, Jesús Prieto, M Gabriela Kramer.   

Abstract

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) often lacks curative treatment; therefore new efficient therapies are needed. In this work we aimed at evaluating the antitumor effect of interleukin-12 (IL-12)-based gene therapy on HCC occurring spontaneously in mice.
METHODS: A plasmid-vector expressing IL-12 in a liver-specific and doxycycline (Dox)-inducible manner was transferred by hydrodynamic injection to the liver of L-PK/c-myc mice with HCC. IL-12 expression was induced by administering Dox (3 cycles of 1 month duration separated by 1 month rest).
RESULTS: Dox administration increased serum IL-12 and IFN-gamma and induced tumor lymphocytic infiltration in all treated mice which was accompanied by tumor stabilization or regression in 40% of animals. The antitumor effect did not correlate with levels of IL-12 or IFN-gamma nor with the intensity of tumor mononuclear infiltration. However, tumors from non-responder mice showed more abundance of Foxp3+ regulatory T cells and higher expression of the immunosuppressive molecules PD-1, PD-L1, VEGF, CTLA-4, IDO, and IL-10 than those that responded to therapy.
CONCLUSIONS: Although long-term induction of IL-12 expression in the liver can inhibit HCC growth, the efficacy of the treatment appears to be limited by the activation of immunosuppressive mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17935823     DOI: 10.1016/j.jhep.2007.07.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  26 in total

1.  Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells.

Authors:  José Medina-Echeverz; Pedro Berraondo
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 2.  Immunological landscape and immunotherapy of hepatocellular carcinoma.

Authors:  Jesús Prieto; Ignacio Melero; Bruno Sangro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-20       Impact factor: 46.802

Review 3.  Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege.

Authors:  Lei Huang; Babak Baban; Burles A Johnson; Andrew L Mellor
Journal:  Int Rev Immunol       Date:  2010-04       Impact factor: 5.311

4.  Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases.

Authors:  José Medina-Echeverz; Jessica Fioravanti; Nancy Díaz-Valdés; Kathrin Frank; Fernando Aranda; Celia Gomar; Nuria Ardaiz; Javier Dotor; Viktor Umansky; Jesús Prieto; Pedro Berraondo
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

Review 5.  Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management.

Authors:  Ken Shirabe; Takashi Motomura; Jun Muto; Takeo Toshima; Rumi Matono; Yohei Mano; Kazuki Takeishi; Hideki Ijichi; Noboru Harada; Hideaki Uchiyama; Tomoharu Yoshizumi; Akinobu Taketomi; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2010-10-21       Impact factor: 3.402

Review 6.  Immune checkpoint inhibitors in gastrointestinal malignancies.

Authors:  Vishal Jindal
Journal:  J Gastrointest Oncol       Date:  2018-04

7.  Effect of dipterinyl calcium pentahydrate on hepatitis B virus replication in transgenic mice.

Authors:  Phillip Moheno; John Morrey; Dietmar Fuchs
Journal:  J Transl Med       Date:  2010-03-31       Impact factor: 5.531

8.  Associations between polymorphisms in IL-12A, IL-12B, IL-12Rβ1, IL-27 gene and serum levels of IL-12p40, IL-27p28 with esophageal cancer.

Authors:  Yi-Peng Tao; Wan-Ling Wang; Song-Yue Li; Jian Zhang; Qi-Zhong Shi; Fen Zhao; Bao-Sheng Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-28       Impact factor: 4.553

9.  Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.

Authors:  Lisa K Jasperson; Christoph Bucher; Angela Panoskaltsis-Mortari; Andrew L Mellor; David H Munn; Bruce R Blazar
Journal:  Blood       Date:  2009-10-14       Impact factor: 22.113

Review 10.  Regulatory T cells and treatment of cancer.

Authors:  Tyler J Curiel
Journal:  Curr Opin Immunol       Date:  2008-05-27       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.